Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
Can J Physiol Pharmacol ; 99(3): 332-347, 2021 Mar.
Article in English | MEDLINE | ID: mdl-32721224

ABSTRACT

Hepatic encephalopathy depicts the cluster of neurological alterations that occur during acute or chronic hepatic injury. Hyperammonemia, inflammatory injury, and oxidative stress are the main predisposing factors for the direct and indirect changes in cerebral metabolism causing encephalopathy. The aim of this study was to evaluate the possible synergistic effect between aminoguanidine (AG; 100 mg/kg, p.o.) and l-carnosine (CAR; 200 mg/kg, p.o.) on hepatic encephalopathy that was induced by thioacetamide (TAA; 100 mg/kg, i.p.) administered three times weekly for six weeks. Behavioral changes, biochemical parameters, histopathological analysis, and immunohistochemical and ultrastructural studies were conducted 24 h after the last treatment. Combining AG with CAR improved TAA-induced locomotor impairment and motor incoordination evidenced by reduced locomotor activity and decline in motor skill performance, as well as ameliorated cognitive deficits. Moreover, both drugs restored the levels of serum hepatic enzymes and serum and brain levels of ammonia. In addition, the combination significantly modulated hepatic and brain oxidative stress biomarkers, inflammatory cytokines, and cleaved caspase-3 expression. Furthermore, they succeeded in activating nuclear erythroid 2-related factor 2 (Nrf2) expression and heme oxygenase-1 (HO-1) activity and ameliorating markers of hepatic encephalopathy, including hepatic necrosis and brain astrocyte swelling. This study shows that combining AG with CAR exerted a new intervention for hepatic and brain damage in hepatic encephalopathy due to their complementary antioxidant, anti-inflammatory effects and hypoammonemic effects via Nrf2/HO-1 activation and NO inhibition.


Subject(s)
Carnosine/therapeutic use , Guanidines/therapeutic use , Hepatic Encephalopathy/prevention & control , Thioacetamide , Ammonia/metabolism , Animals , Behavior, Animal , Brain/pathology , Brain Chemistry/drug effects , Drug Synergism , Hepatic Encephalopathy/chemically induced , Hepatic Encephalopathy/psychology , Liver/pathology , Liver Function Tests , Male , Motor Activity/drug effects , Motor Skills/drug effects , Rats , Rats, Wistar
2.
Can J Physiol Pharmacol ; 95(4): 427-436, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28157387

ABSTRACT

The present study aimed to evaluate the effect of trigonelline (TRG) on the hepatic complications associated with high-fat high-fructose (HFHF) diet-induced insulin resistance (IR) in rats. IR was induced by giving a saturated fat diet and 10% fructose in drinking water to rats for 8 weeks. Insulin-resistant rats were orally treated with TRG (50 and 100 mg/kg), sitagliptin (SIT; 5 mg/kg), or a combination of TRG (50 mg/kg) and SIT (5 mg/kg) for 14 days. Liver homogenates were used for assessment of hepatic lipids, oxidative stress biomarkers, and inflammatory cytokines. Histopathological and DNA cytometry examinations were carried out for hepatic and pancreatic tissues. Hepatic tissues were examined using Fourier-transform infrared spectroscopy for assessment of any molecular changes. Results of the present study revealed that oral treatment of insulin-resistant rats with TRG or TRG in combination with SIT significantly decreased homeostatic model assessment of IR, hepatic lipids, oxidative stress biomarkers, and the inflammatory cytokines. TRG or TRG in combination with SIT ameliorated the histopathological, DNA cytometry, and molecular alterations induced by a HFHF diet. Finally, it can be concluded that TRG has beneficial effects on the hepatic complications associated with IR due to its hypoglycemic effect and antioxidant potential.


Subject(s)
Alkaloids/therapeutic use , Antioxidants/therapeutic use , Hypoglycemic Agents/therapeutic use , Metabolic Syndrome/complications , Non-alcoholic Fatty Liver Disease/drug therapy , Sitagliptin Phosphate/therapeutic use , Animals , Biomarkers/analysis , Blood Glucose/analysis , Cytokines/analysis , Diet, Carbohydrate Loading/adverse effects , Diet, High-Fat/adverse effects , Dipeptidyl-Peptidase IV Inhibitors/therapeutic use , Disease Models, Animal , Drug Evaluation, Preclinical , Drug Therapy, Combination , Humans , Lipids/analysis , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Metabolic Syndrome/etiology , Non-alcoholic Fatty Liver Disease/etiology , Oxidative Stress/drug effects , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL